Bio Pharma Acquires IP and HR Assets of BLS
News Aug 26, 2016
Bio Pharma Services, Inc. has announced that it has acquired key human resource assets along with a list of validated assays from Bioanalytical Laboratory Services (BLS). Over the past 3 years, BLS, led by Lab Director, Nicola Hughes, Ph.D., has built a leading bioanalytical research centre specializing in complex method development, method validation and the analysis of biological samples for pre-clinical and clinical drug trials (BA/BE studies). BLS assets will be combined with Bio Pharma’s existing Bioanalytical Lab to further expand and fortify its analytical services and become a global leader in clinical research.
“We are very proud to combine the best of Bio Pharma’s existing bioanalytical lab with the best of BLS. Under the scientific leadership of Dr. Hughes, the expanded lab at Bio Pharma will be able to immediately offer challenging and complex new assays while strengthening our Scientific R&D team. This is just one of a list of benefits associated with merging the assets of two great labs at Bio Pharma.” said Renzo DiCarlo, CEO at Bio Pharma Services, Inc.
Effective immediately, Dr. Hughes will be appointed to the Bio Pharma Executive Team as the Vice- President of Lab Operations. “I am extremely excited about my team joining the Bio Pharma team and believe together, by offering scientific excellence, high quality assays and our commitment to providing exceptional service to our clients, we are ideally suited for the early stage research market.”
With this news, existing BLS client projects will be honoured and completed as planned at the current BLS facility. Anna Taylor, Vice-President of Business Development reiterated, “We truly are a client centered organization driven by science and quality research. I am excited that we have this opportunity to share our expanded BA lab expertise and service for both past and future clients under this new team at Bio Pharma.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018